BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Focosi D, Franchini M, Pirofski LA, Maggi F, Casadevall A. Is SARS-CoV-2 viral clearance in nasopharyngeal swabs an appropriate surrogate marker for clinical efficacy of neutralising antibody-based therapeutics? Rev Med Virol 2021;:e2314. [PMID: 34861088 DOI: 10.1002/rmv.2314] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
Number Citing Articles
1 Focosi D, Casadevall A. A Critical Analysis of the Use of Cilgavimab plus Tixagevimab Monoclonal Antibody Cocktail (Evusheld™) for COVID-19 Prophylaxis and Treatment. Viruses 2022;14:1999. [PMID: 36146805 DOI: 10.3390/v14091999] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
2 Rivero R, Garay E, Botero Y, Serrano-Coll H, Gastelbondo B, Muñoz M, Ballesteros N, Castañeda S, Patiño LH, Ramirez JD, Calderon A, Guzmán C, Martinez-Bravo C, Aleman A, Arrieta G, Mattar S. Human-to-dog transmission of SARS-CoV-2, Colombia. Sci Rep 2022;12:7880. [PMID: 35551247 DOI: 10.1038/s41598-022-11847-9] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
3 Salehi-Vaziri M, Fazlalipour M, Seyed Khorrami SM, Azadmanesh K, Pouriayevali MH, Jalali T, Shoja Z, Maleki A. The ins and outs of SARS-CoV-2 variants of concern (VOCs). Arch Virol 2022. [PMID: 35089389 DOI: 10.1007/s00705-022-05365-2] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 8.0] [Reference Citation Analysis]
4 Focosi D, Maggi F, Franchini M, McConnell S, Casadevall A. Analysis of Immune Escape Variants from Antibody-Based Therapeutics against COVID-19: A Systematic Review. Int J Mol Sci 2021;23:29. [PMID: 35008446 DOI: 10.3390/ijms23010029] [Cited by in Crossref: 17] [Cited by in F6Publishing: 20] [Article Influence: 8.5] [Reference Citation Analysis]